Osmotica Pharmaceuticals PLC to Discuss Recent UPNEEQ Trends Corporate Call Transcript
Welcome to the RVL Pharmaceuticals UPNEEQ Business Update Call. This is Lisa Wilson, Investor Relations for RVL Pharmaceuticals. Hosting today's call are RVL's Chief Executive Officer, Brian Markison; and Chief Operating Officer, JD Schaub.
This morning, the company issued a press release detailing its name change, its new ticker symbol on NASDAQ, RVLP, and the company's launch into medical aesthetics, along with certain key financial and commercial metrics. This press release and a webcast of this call can be accessed through the Investors section of the RVL website at rvlpharma.com.
Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements.
These forward-looking statements include statements regarding the company's intentions, beliefs and expectations concerning, among other things, our results of operations, including revenue for Q4 2022
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |